Midodrine

證據等級: L5

預測適應症: 10 個

Midodrine: From Hypotensive Disorder to Variably Protease-Sensitive Prionopathy

One-Sentence Summary

Midodrine is a peripheral α1-adrenergic agonist whose established clinical use — reflected in this same evidence pack as the "hypotensive disorder" prediction (9 trials, 19 publications) — is treating orthostatic hypotension. The TxGNN model's top-ranked prediction, however, is Variably Protease-Sensitive Prionopathy, a rare prion disease, with a score of 99.99% but zero clinical trials and zero publications supporting any connection, and no plausible mechanistic link to the drug's pharmacology.

Quick Overview

Item	Content
Original Indication	Not stated in evidence pack (no NZ licenses on file); midodrine's known clinical role corresponds to "hypotensive disorder," which independently ranks #4 in this same prediction set with strong supporting evidence
Predicted New Indication	Variably Protease-Sensitive Prionopathy
TxGNN Prediction Score	99.99%
Evidence Level	L5
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not returned for this drug (original_moa: [Data Gap]). Based on known pharmacology, midodrine is a prodrug converted to its active metabolite desglymidodrine, a peripheral α1-adrenergic receptor agonist that causes vasoconstriction and raises blood pressure — the basis for its established use in orthostatic/hypotensive disorders (consistent with the strong trial and literature base seen under the "hypotensive disorder" candidate elsewhere in this evidence pack).

Variably Protease-Sensitive Prionopathy (VPSPr) is a rare, sporadic human prion disease driven by abnormal, protease-sensitive misfolded prion protein and progressive neurodegeneration. There is no established pathway connecting peripheral α1-adrenergic vasoconstriction to prion protein misfolding or neurodegeneration, and the drug's evidence pack explicitly notes the pathology and MOA have no reasonable link.

This candidate therefore reflects a high raw model score with no accompanying mechanistic, preclinical, clinical, or literature support — the pattern the evidence level rubric classifies as L5 (model prediction only).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

New Zealand Market Information

Midodrine is not currently marketed in New Zealand (0 authorizations on file), so no product/license table is available.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data were all returned as data gaps or not found in this evidence pack.)

Conclusion and Next Steps

Decision: Hold

Rationale:

The 99.99% TxGNN score is not corroborated by any clinical trial, publication, or plausible mechanism — this is a pure model artifact rather than a repurposing signal, and the evidence pack's own rationale confirms no known link between α1-agonism and prion disease pathology.
Separately, a critical safety data gap (DG001, Blocking) means midodrine cannot yet enter S1 safety evaluation for any new indication regardless of efficacy signal.

To proceed, the following is needed:

TFDA/official package insert (warnings, contraindications) to clear the Blocking safety gap (DG001) before any indication — including this one — can enter S1 review
Confirmed mechanism-of-action documentation (DG002) via DrugBank or equivalent
If pursuing repurposing for this drug, prioritize higher-evidence candidates already present in this same evidence pack — notably rank 4 "hypotensive disorder" (L4, 9 trials, 19 publications) — over this L5 candidate
Preclinical or biological plausibility data specifically linking adrenergic agonism to prion disease, if this candidate is to be revisited
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.